Samsung Biologics to Add mRNA Capabilities to South Korea Facility

Pharmaceutical Technology Editors

Expected to be completed by 2022, the new addition is part of the Samsung Biologics’ long-term strategy to become a fully integrated global biopharmaceutical company.

Samsung Biologics announced on May 31, 2021 that it plans to add messenger RNA (mRNA) vaccine drug substance manufacturing capabilities to its facility in Songdo, South Korea.

Expected to be completed by 2022, the new addition is part of the company’s long-term strategy to become a fully integrated global biopharmaceutical company, Samsung Biologics said in a company press release.

“We are constantly assessing various ways that we can expand and persify our current business portfolio to better serve the market,” said John Rim, CEO of Samsung Biologics, in the press release. “We are committed to helping our clients provide quality treatments and vaccines to all those in need around the world, especially in difficult times like this, and with this extended capability, we hope to support our partners in bringing novel mRNA vaccines and therapeutics to market at a faster pace.”

Source: Samsung Biologics